Edition:
United States

Exelixis Inc (EXEL.OQ)

EXEL.OQ on NASDAQ Stock Exchange Global Select Market

15.45USD
4:00pm EDT
Change (% chg)

$-0.82 (-5.04%)
Prev Close
$16.27
Open
$16.44
Day's High
$16.59
Day's Low
$15.43
Volume
893,349
Avg. Vol
1,276,050
52-wk High
$32.20
52-wk Low
$15.43

Chart for

About

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's... (more)

Overall

Beta: 2.15
Market Cap(Mil.): $5,170.92
Shares Outstanding(Mil.): 298.04
Dividend: --
Yield (%): --

Financials

  EXEL.OQ Industry Sector
P/E (TTM): 16.81 119.85 32.14
EPS (TTM): 1.03 -- --
ROI: 52.55 1.96 12.83
ROE: 70.00 1.12 14.95

BRIEF-Exelixis Appoints Andrew Peters To Newly Created Position Of Vice President, Strategy

* EXELIXIS APPOINTS ANDREW R. PETERS TO NEWLY CREATED POSITION OF VICE PRESIDENT, STRATEGY Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-Exelixis Says Phase 3 Imblaze370 Study Did Not Meet Its Primary Endpoint Of Improving Overall Survival Vs Regorafenib

* EXELIXIS PROVIDES UPDATE ON IMBLAZE370 PHASE 3 PIVOTAL TRIAL OF ATEZOLIZUMAB AND COBIMETINIB IN PATIENTS WITH HEAVILY PRETREATED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER

May 10 2018

BRIEF-Exelixis Inc Q1 Earnings Per Share $0.37

* EXELIXIS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 02 2018

BRIEF-Exelixis And Invenra Enter Into Collaboration To Develop Novel Biologics To Treat Cancer

* EXELIXIS AND INVENRA ENTER INTO COLLABORATION TO DISCOVER AND DEVELOP NOVEL BIOLOGICS TO TREAT CANCER

May 02 2018

Earnings vs. Estimates